Effects of ticlopidine in AV-fistula surgery in uremia

Scandinavian Journal of Urology and Nephrology

Volumn 32, Issue 4, 1998, Pages 276-283

  Gröntoft, Knut Christian ^a   Larsson, Rutger ^b   Mulec, Henrik ^c   Weiss, Lars G ^d   Dickinson, John P ^e  

^a Eskilstuna Central Hospital   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c Tees Esk and Wear Valley NHS Trust   (United Kingdom)

^d Karlstad Central Hospital   (United Kingdom)

^e Sanofi Winthrop Ltd   (United Kingdom)

Author keywords

Arteriovenous fistula; Surgery; Ticlopidine; Uremia thrombosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; MELPHALAN; PLACEBO; PREDNISONE; TICLOPIDINE;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME; UREMIA;

EID: 0031840374     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655998750015458     Document Type: Article

References (25)

1. Albert FW, Schmidt U. Sulphinpyrazone or acetyl-salicylic acid to prevent postoperative thrombus formtion in arteriovenous fistulas of haemodialysis patients. Haemostasis 1979: 42, 63, Abstract 0140.
2. Andrassy K, Malluche H, Bornefeld H, et al. Prevention of p.o. clotting of AV Cimino fistulae with acetyl-salicylic acid: results of a prospective double blind study. Klin Wschr 1974; 52: 348-349.
3. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320-331.
4. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-II: Maintenance of vascular graft or arterial patency by antiplatet therapy. Br Med J 1994; 308: 159-168.
5. Brescia MJ, Cimino JE, Appel K, Hurwich BJ. Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula. New Eng J Med 1966; 275: 1089-1093.
6. Dodd NJ, Turney JH, Weston MJ. Ticlopidine preserves vascular access for haemodialysis. 6th Congress of the Ligue Mediterranéenne contre les Maladies Thromboemboliques. Monte Carlo, 23-25 October, 1980: Abstract 326F.
7. Ell S, Mihindukulasuriya JCL, O'Brien JR, Polak A, Vernham G. Ticlopidine in the prevention of blockage of fistulae and shunts. Haemostasis 1982; 12: 180, Abstract 332.
8. Fiskerstrand CE, Thompson IW, Burnet ME, Williams P, Anderton JL. Double blind randomised trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artif Organs 1985; 9: 61-63.
9. Galato R, Bertoli S, Mandolfo S. Prevenzione dell'occlusione trombotica dell'accesso vascolare alla emodialisi con ticlopidina. In: Anonyme. Recenti acquisizione in tema di terapia antipiastrinice: Simposio satellite all'83 Congresso Della Societa Italiana Di Medicina Interna, Roma 20 Ottobre 1982. Milan, Masson, 1982: 185-189.
10. Gent M, Blakely JA, Easton JD, et al. The Canadian-American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989; i: 1215-1220.
11. Gröntoft K-CH, Mulec H, Guiterez A, Olander R. Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scand J Urol Nephrol 1985; 19: 55-57.
12. Hass WK, Easton JD, Adams HP, et al. for the Ticlopidine Aspirin Stroke Study Group. A randomised trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. New Engl J Med 1989; 321: 501-507.
13. Harter HR, Burch JW, Majerus PW, et al. Prevention of thrombosis in patients on haemodialysis by low-dose aspirin. New Eng J Med 1979; 301: 577-579.
14. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication: Effects of ticlopidine. Results from Stims, the Swedish ticlopidine multicentre study. J Internal Med 1990; 227: 301-308.
15. Kaegi A, Pineo GF, Shimizu A, Trivedi H, Hirsch J, Gent M. Arteriovenous-shunt thrombosis: prevention by sulphinpyrazone. New Eng J Med 1974; 290: 304-306.
16. Kinnaert P, Vereerstraeten P, Toussaint C, Van Geertruyden J. Nine year's experience with internal arteriovenous fistulas for haemodialysis. A study of some factors influencing the results. Br J Surg 1974; 64: 242-246.
17. Kobayashi K, Maeda K, Koshikawa S, Kawaguchi Y, Shimizu N, Naito C. Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis. A multicenter collaborative double blind study. Thrombosis Res 1980; 20: 255-261.
18. McArdle CS, Hole D. Impact of variability among surgeons on post-operative morbidity and mortality and ultimate survival. Br Med J 1991; 302: 1501-1505.
19. McTavish D, Faulds D, Goa KL. Ticlopidine: An updated review of its phamacology and therapeutic use in platelet-dependent disorders. Drugs 1990; 40: 238-259.
20. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 103-115.
21. Rohr MS, Browder W, Frentz GD, McDonald JC. Arteriovenous fistulas for long-term dialysis. Arch Surg 1978; 113: 153-155.
22. Saltiel E, Ward A. Ticlopidine: a review of its pharmacodynamic and pharmakokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987; 34: 222-262.
23. SAS Institute, Inc. User's Guide: Statistics., Version 5. Cary NC (ED). SAS Institute Inc. 1985.
24. Thompson BW, Barbour G, Bissett J. Internal arteriovenous fistula for hemodialysis. Am J Surg 1972; 124: 785-788.
25. Thomsen MB, Deurell D-I, Elfström J, Alm A. What causes the failure of arteriovenous fistulas? Acta Chir Scand 1983; 149: 371-376.